

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. – 15. (Cancelled).
16. (New) A method for treating a mammal suffering from a localized bacterial infection or a bacterial-related disease comprising administering a therapeutically effective amount of a composition comprising at least one Colony Stimulating Factor (CSF) polypeptide or fragment or derivative thereof having essentially the biological function and activity of the CSF.
17. (New) The method of claim 16, wherein the bacterial infection or bacterial-related disease is selected from periodontal disease or sinusitis.
18. (New) The method of claim 17, wherein the periodontal disease is gingivitis or periodontitis.
19. (New) The method of claim 16, wherein the CSF polypeptide is selected from granulocyte-colony stimulating factor (G-CSF), macrophage-colony stimulating factor (M-CSF), granulocyte-macrophage-colony stimulating factor (GM-CSF), and multi-colony stimulating factor (multi-CSF).
20. (New) The method of claim 19, wherein the CSF is GM-CSF.
21. (New) The method of claim 16, wherein the composition is suitable for administration via injection through the mucosal lining of the gingival or by application in a periodontal pocket.

22. (New) The method of claim 16, wherein the CSF or fragment or derivative thereof is present in the composition in a unit dosage amount of 5 μ g to 800 μ g.

23. (New) The method of claim 22, wherein the unit dosage amount is 50 μ g to 100 μ g.

24. (New) The method of claim 16, wherein the composition is administered at intervals ranging from once a day to once every third week.

25. (New) The method of claim 16, wherein the composition is administered a total of 1 to 3 times for a period of one week.

26. (New) The method of claim 16, wherein the composition comprises a therapeutically effective amount of at least one other active ingredient.

27. (New) The method of claim 16, wherein the CSF or fragment or derivative thereof is produced by means of a recombinant expression system.

28. (New) A composition for treating a localized bacterial infection or bacterial related disease comprising a therapeutically effective amount of at least one Colony Stimulating Factor (CSF) polypeptide or fragment or derivative thereof.

29. (New) A composition for treating a localized bacterial infection or bacterial related disease comprising a therapeutically effective amount of a granulocyte-macrophage-colony stimulating factor (GM-CSF) polypeptide or fragment or derivative thereof.